1. Real-world experience of off-label use of imiquimod 5% as an adjuvant therapy after surgery or as a monotherapy for lentigo maligna
- Author
-
Caterina Longo, Luc Thomas, Giuseppe Argenziano, Harald Kittler, Sofia-Magdalini Manoli, Elvira Moscarella, Zoe Apalla, Chryssoula Papageorgiou, N. Di Meo, Iris Zalaudek, A Kyrgidis, Aimilios Lallas, Lallas, A, Moscarella, E, Kittler, H, Longo, C, Thomas, L, Zalaudek, I, Kyrgidis, A, Manoli, S M, di Meo, N, Papageorgiou, C, Apalla, Z, Argenziano, G, Lallas, A., Moscarella, E., Kittler, H., Longo, C., Thomas, L., Zalaudek, I., Kyrgidis, A., Manoli, S. M., di Meo, N., Papageorgiou, C., Apalla, Z., and Argenziano, G.
- Subjects
melanoma ,lentigo maligna ,imiquimod ,treatment ,mohs' surgery ,recurrence ,medicine.medical_specialty ,Skin Neoplasms ,MEDLINE ,Imiquimod ,Antineoplastic Agents ,Dermatology ,Lentigo maligna ,Off-label use ,Antineoplastic Agent ,Hutchinson's Melanotic Freckle ,Aminoquinoline ,medicine ,Adjuvant therapy ,Humans ,business.industry ,Off-Label Use ,medicine.disease ,Aminoquinolines ,business ,Human ,medicine.drug - Abstract
Because of the tendency of lentigo maligna (LM) for subclinical extension, staged excisions with margin control achieve lower recurrence rates than conventional wide local excision (0-9.5% vs 8-20%). However, these surgical techniques are limited by their requirement in time, costs and training.
- Published
- 2021